Agenus (AGEN) Stock Forecast & Price Target

Agenus is a clinical-stage biotechnology company that operates in the United States and other international markets, with a primary focus on immuno-oncology. Its botensilimab (BOT) and balstilimab (BAL) combination therapy has shown positive results in clinical trials, including a ~30% pCR rate and a ~65% PR rate, superior to rates observed in previous trials. With a potentially extended patent life until 2042 and low rates of treatment-related Grade 3 events, Agenus's BOT/BAL therapy has a high likelihood of success in its ongoing ROBBIN trial, which could lead to a significant increase in the company's shareholder value.

Agenus is facing significant financial challenges and risks, as seen in their 2Q26 financial report, as operating expenses have increased and cash on hand is low. The recent shift in strategy to focus on neoadjuvant therapy for MSS-CRC is risky and may not yield positive results. There are also potential risks such as safety concerns and competition for their programs. These factors contribute to our negative outlook on the company's stock.